Gemcitabine plus pemetrexed promising in advanced NSCLC

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1460, 2004-01, pp. : 15-15

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Gemcitabine plus cisplatin for NSCLC

By  

Inpharma, Vol. 1, Iss. 1222, 2000-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Docetaxel plus gemcitabine shows antitumour efficacy in patients with advanced NSCLC

By  

Inpharma, Vol. 1, Iss. 1280, 2001-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

Gemcitabine plus vinorelbine superior in NSCLC

By  

Inpharma, Vol. 1, Iss. 1251, 2000-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

Phase I/II trial of gemcitabine plus docetaxel in advanced non small cell lung cancer (NSCLC)

By Israel Valerie   Tagawa Scott   Snyder Terry   Jeffers Susan   Raghavan Derek  

Investigational New Drugs, Vol. 22, Iss. 3, 2004-08 ,pp. : 291-297

Springer Publishing Company

Access to resources Recommend Favorite

Cisplatin + pemetrexed as first-line therapy for advanced NSCLC

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 593, 2009-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite